Enterprise Value to EBITDA (EV/EBITDA)
Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Moderna Inc., EBITDA calculation
US$ in millions
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
| Item | Description | The company |
|---|---|---|
| EBITDA | To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. | Moderna Inc. EBITDA decreased from 2021 to 2022 and from 2022 to 2023. |
Enterprise Value to EBITDA Ratio, Current
Moderna Inc., current EV/EBITDA calculation, comparison to benchmarks
| Selected Financial Data (US$ in millions) | |
| Enterprise value (EV) | 11,320) |
| Earnings before interest, tax, depreciation and amortization (EBITDA) | (3,283) |
| Valuation Ratio | |
| EV/EBITDA | — |
| Benchmarks | |
| EV/EBITDA, Competitors1 | |
| AbbVie Inc. | 28.06 |
| Amgen Inc. | 15.79 |
| Bristol-Myers Squibb Co. | 7.27 |
| Danaher Corp. | 22.57 |
| Eli Lilly & Co. | 56.39 |
| Gilead Sciences Inc. | 14.74 |
| Johnson & Johnson | 16.26 |
| Merck & Co. Inc. | 36.83 |
| Pfizer Inc. | 21.82 |
| Regeneron Pharmaceuticals Inc. | 13.21 |
| Thermo Fisher Scientific Inc. | 19.71 |
| Vertex Pharmaceuticals Inc. | 24.74 |
| EV/EBITDA, Sector | |
| Pharmaceuticals, Biotechnology & Life Sciences | 23.18 |
| EV/EBITDA, Industry | |
| Health Care | 19.42 |
Based on: 10-K (reporting date: 2023-12-31).
1 Click competitor name to see calculations.
If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
Moderna Inc., historical EV/EBITDA calculation, comparison to benchmarks
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Enterprise value (EV)1 | 28,826) | 44,973) | 51,004) | 57,415) | 8,579) | |
| Earnings before interest, tax, depreciation and amortization (EBITDA)2 | (3,283) | 9,952) | 13,535) | (703) | (477) | |
| Valuation Ratio | ||||||
| EV/EBITDA3 | — | 4.52 | 3.77 | — | — | |
| Benchmarks | ||||||
| EV/EBITDA, Competitors4 | ||||||
| AbbVie Inc. | 20.79 | 13.31 | 13.44 | 21.34 | — | |
| Amgen Inc. | 14.13 | 12.97 | 13.22 | 12.24 | — | |
| Bristol-Myers Squibb Co. | 6.51 | 9.46 | 8.65 | 34.35 | 23.84 | |
| Danaher Corp. | 26.41 | 18.42 | 21.05 | 26.68 | — | |
| Eli Lilly & Co. | 85.33 | 37.74 | 29.85 | 23.67 | — | |
| Gilead Sciences Inc. | 10.41 | 13.89 | 8.57 | 24.90 | 11.77 | |
| Johnson & Johnson | 16.45 | 14.78 | 14.47 | 18.20 | — | |
| Merck & Co. Inc. | 51.30 | 13.91 | 12.18 | 16.05 | 13.66 | |
| Pfizer Inc. | 22.50 | 6.12 | 8.64 | 15.78 | 9.17 | |
| Regeneron Pharmaceuticals Inc. | 20.16 | 15.27 | 6.68 | 12.70 | — | |
| Thermo Fisher Scientific Inc. | 21.83 | 20.25 | 20.21 | 18.72 | — | |
| Vertex Pharmaceuticals Inc. | 21.57 | 14.91 | 18.92 | 14.81 | 37.82 | |
| EV/EBITDA, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 22.59 | 13.58 | 13.16 | 18.90 | — | |
| EV/EBITDA, Industry | ||||||
| Health Care | 18.98 | 13.71 | 13.87 | 16.50 | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
3 2023 Calculation
EV/EBITDA = EV ÷ EBITDA
= 28,826 ÷ -3,283 = —
4 Click competitor name to see calculations.